CytomX Therapeutics Inc (NASDAQ:CTMX) has been given an average recommendation of “Buy” by the fourteen research firms that are currently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $20.91.

Several brokerages recently commented on CTMX. Zacks Investment Research downgraded shares of German American Bancorp. from a “buy” rating to a “hold” rating in a research note on Tuesday, April 30th. HC Wainwright reissued a “buy” rating and issued a $1.75 price objective on shares of Orion Energy Systems in a research note on Wednesday, April 3rd. Mizuho began coverage on shares of CytomX Therapeutics in a research note on Wednesday, June 12th. They issued a “buy” rating and a $16.00 price objective for the company. BidaskClub raised shares of Westport Fuel Systems from a “hold” rating to a “buy” rating in a research note on Friday. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $23.00 price objective (up previously from $21.00) on shares of CytomX Therapeutics in a research note on Monday, June 3rd.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. First Trust Advisors LP acquired a new position in CytomX Therapeutics in the 1st quarter valued at approximately $263,000. DekaBank Deutsche Girozentrale increased its position in CytomX Therapeutics by 21.5% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 14,700 shares of the biotechnology company’s stock valued at $334,000 after acquiring an additional 2,600 shares during the period. Fosun International Ltd increased its position in CytomX Therapeutics by 48.8% in the 1st quarter. Fosun International Ltd now owns 52,445 shares of the biotechnology company’s stock valued at $551,000 after acquiring an additional 17,200 shares during the period. Pictet Asset Management Ltd. increased its position in CytomX Therapeutics by 0.9% in the 1st quarter. Pictet Asset Management Ltd. now owns 611,356 shares of the biotechnology company’s stock valued at $6,572,000 after acquiring an additional 5,670 shares during the period. Finally, Acadian Asset Management LLC acquired a new position in CytomX Therapeutics in the 1st quarter valued at approximately $1,293,000. Hedge funds and other institutional investors own 81.83% of the company’s stock.

NASDAQ:CTMX traded up $0.03 on Friday, hitting $11.82. The company had a trading volume of 448,610 shares, compared to its average volume of 363,319. The stock has a market cap of $535.56 million, a PE ratio of -5.82 and a beta of 0.64. The company has a quick ratio of 4.21, a current ratio of 4.21 and a debt-to-equity ratio of 0.22. The company’s 50 day moving average price is $10.75. CytomX Therapeutics has a 52 week low of $8.94 and a 52 week high of $27.20.

CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.31) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.53) by $0.22. The business had revenue of $29.49 million during the quarter, compared to the consensus estimate of $13.59 million. CytomX Therapeutics had a negative net margin of 111.27% and a negative return on equity of 73.62%. As a group, equities analysts expect that CytomX Therapeutics will post -2.13 earnings per share for the current fiscal year.

About CytomX Therapeutics

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.

Read More: What is the return on assets (ROA) ratio?

Analyst Recommendations for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.